Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 15 of 15 results for iapt

  1. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

  2. Alpha-Stim AID for anxiety disorders (MTG56)

    Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.

  3. Anxiety disorders (QS53)

    This quality standard covers identifying and managing anxiety disorders in adults, young people and children in primary, secondary and community care. It covers a range of anxiety disorders, including generalised anxiety disorder, social anxiety disorder, post-traumatic stress disorder, panic disorder, obsessive-compulsive disorder and body dysmorphic disorder. It describes high-quality care in priority areas for improvement.

  4. Depression and anxiety: recovery post-IAPT (IND37)

    This indicator covers the proportion of people treated by Improving Access to Psychological Therapies (IAPT) for anxiety disorders who return to full function. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG54

  5. What is NICE doing next?

    guidance. For example: The Adult Improving Access to Psychological Therapies (IAPT) programme has been developed to increase access to...

  6. Management of inflammatory arthritis

    to continue the expansion of Improving Access to Psychological Therapies (IAPT) services for adults and older adults with common mental...

  7. Maternity and mental health

    secondary care mental health and Improving Access to Psychological Therapies (IAPT) services to benchmark performance against NICE...

  8. Depression in children and young people (QS48)

    This quality standard covers diagnosing and managing depression in children and young people (aged 5 to 18). It describes high-quality care in priority areas for improvement.

  9. Digitally enabled therapies for adults with depression: early value assessment (HTE8)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....

  10. Workplace health: long-term sickness absence and capability to work (NG146)

    This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.

  11. Routine outcome measurement:- In people with a common mental health disorder, what is the clinical utility of routine outcome measurement and is it cost effective compared with standard care?

    interventions, particularly in the Improving Access to Psychological Therapies (IAPT) programme. There is evidence from this programme...

  12. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTE9)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders....

  13. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

  14. Computerised cognitive behaviour therapy for depression and anxiety (TA97)

    The guidance was withdrawn in July 2018 to allow OCFighter to be considered for an improving access to psychological therapies assessment briefing. If OCFighter is not selected, it may be considered for a medtech innovation briefing.

  15. Adults with depression who want to quit antidepressants should be given support

    Adults with depression who want to stop taking antidepressants should have the dose of their medication reduced in stages to reduce the likelihood and severity of withdrawal symptoms, NICE has said.